How does EGRX's PE Ratio compare to its peers?

EGRX is good value based on its Price-To-Earnings Ratio (0.9x) compared to the peer average (8.5x).

How does EGRX's PE Ratio compare vs other companies in the US Biotechs Industry?

EGRX is good value based on its Price-To-Earnings Ratio (0.9x) compared to the US Biotechs industry average (17x).

What is EGRX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate EGRX's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of EGRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate EGRX's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Eagle Pharmaceuticals (OTCPK:EGRX) - Stock Price, News & Analysis

EGRX Stock Overview

A pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States.

About the company

EGRX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	1/6
Financial Health	4/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (0.9x) is below the US market (19x)

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

Revenue has declined by 5.4% over the past year

Latest financial reports are more than a year old

Profit margins (4.6%) are lower than last year (8.4%)

+ 1 more risk

Eagle Pharmaceuticals, Inc. Competitors

Enzon Pharmaceuticals

OTCPK:ENZN

US$6.3m

PharmaCyte Biotech

NasdaqCM:PMCB

US$13.9m

MEI Pharma

NasdaqCM:MEIP

US$20.3m

Spero Therapeutics

NasdaqGS:SPRO

US$70.8m

Price History & Performance

Summary of all time highs, changes and price drops for Eagle Pharmaceuticals
Historical stock prices
Current Share Price	US$0.85
52 Week High	US$9.89
52 Week Low	US$0.0025
Beta	0.62
11 Month Change	-8.49%
3 Month Change	-79.19%
1 Year Change	-90.82%
33 Year Change	-98.35%
5 Year Change	-98.51%
Change since IPO	-93.37%

Recent updates

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Oct 27

Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia

Oct 12

Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose

Sep 27

Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court

Aug 18

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Aug 15

Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M

Aug 09

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Jul 06

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Apr 29

Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt?

Dec 16

Shareholder Returns

	EGRX	US Biotechs	US Market
7D	54.7%	4.3%	5.0%
1Y	-90.8%	29.9%	36.1%

Return vs Industry: EGRX underperformed the US Biotechs industry which returned 29.2% over the past year.

Return vs Market: EGRX underperformed the US Market which returned 37.7% over the past year.

Price Volatility

Is EGRX's price volatile compared to industry and market?
EGRX volatility
EGRX Average Weekly Movement	45.1%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.2%
10% least volatile stocks in US Market	2.9%

Stable Share Price: EGRX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: EGRX's weekly volatility has increased from 25% to 45% over the past year.

About the Company

Founded	Employees	CEO	Website
2007	134	Mike Graves	www.eagleus.com

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock.

Eagle Pharmaceuticals, Inc. Fundamentals Summary

How do Eagle Pharmaceuticals's earnings and revenue compare to its market cap?
EGRX fundamental statistics
Market cap	US$11.04m
Earnings (TTM)	US$11.95m
Revenue (TTM)	US$257.55m

0.9x

P/E Ratio

0.0x

P/S Ratio

Is EGRX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EGRX income statement (TTM)
Revenue	US$257.55m
Cost of Revenue	US$77.68m
Gross Profit	US$179.88m
Other Expenses	US$167.93m
Earnings	US$11.95m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	0.92
Gross Margin	69.84%
Net Profit Margin	4.64%
Debt/Equity Ratio	27.8%

How did EGRX perform over the long term?

See historical performance and comparison

EGRX Stock Overview

Rewards

Risk Analysis

Eagle Pharmaceuticals, Inc. Competitors

OTCPK:ENZN

US$6.3m

NasdaqCM:PMCB

US$13.9m

NasdaqCM:MEIP

US$20.3m

NasdaqGS:SPRO

US$70.8m

Price History & Performance

Recent News & Updates

Hearings Panel of The Nasdaq Stock Market LLC Determines to Delist Eagle Pharmaceuticals' Common Stock from Nasdaq

Eagle Pharmaceuticals, Inc.(OTCPK:EGRX) dropped from NASDAQ Composite Index

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing

Eagle Pharmaceuticals, Inc. and Curia Global, Inc. Enters into Settlement Agreement in AAA Case No. 01-23-0000-2937

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 3000 Index

Recent updates

Hearings Panel of The Nasdaq Stock Market LLC Determines to Delist Eagle Pharmaceuticals' Common Stock from Nasdaq

Eagle Pharmaceuticals, Inc.(OTCPK:EGRX) dropped from NASDAQ Composite Index

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing

Eagle Pharmaceuticals, Inc. and Curia Global, Inc. Enters into Settlement Agreement in AAA Case No. 01-23-0000-2937

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 3000 Index

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K

Eagle Pharmaceuticals, Inc. announced delayed annual 10-K filing

Eagle Pharmaceuticals, Inc. Announces Board and Committee Changes

New minor risk - Financial data availability

Investor sentiment improves as stock rises 19%

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Eagle Pharmaceuticals, Inc

Eagle Pharmaceuticals, Inc. Announces Resignation of Scott Tarriff as Chief Executive Officer

Eagle Pharmaceuticals, Inc. announced delayed 10-Q filing

Eagle Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Investor sentiment deteriorates as stock falls 32%

Eagle Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Founder notifies of intention to sell stock

Centers for Medicare & Medicaid Services Establishes Unique, Product-Specific Billing Code and Grants Transitional Pass-Through Payment Status for Barhemsys (Amisulpride) Injection by Eagle Pharmaceuticals, Inc

Founder notifies of intention to sell stock

Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?

Investor sentiment deteriorates as stock falls 18%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Eagle Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Eagle Pharmaceuticals, Inc. Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, A Novel First-In-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia

Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from Russell 2000 Growth-Defensive Index

Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly

New major risk - Revenue and earnings growth

Eagle Pharmaceuticals, Inc. Receives FDA Qualified Infectious Disease Product (Qidp) and Fast-Track Designation for Cal02, Providing Five-Year Exclusivity Extension

Founder recently sold US$931k worth of stock

Founder notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates fall by 20%

Eagle Pharmaceuticals, Inc. Receives FDA Approval for Additional Indication for PEMFEXY in Combination with Pembrolizumab and Platinum Chemotherapy

Consensus forecasts updated

Insufficient new directors

Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Eagle Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Eagle Pharmaceuticals, Inc Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CAL02

Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia

Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose

Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) completed the acquisition of Tyme Technologies, Inc. (NasdaqCM:TYME) from a group of shareholders.

Independent Director recently sold US$211k worth of stock

Insufficient new directors

U.S. Court of Appeals for the Federal Circuit Affirms the U.S. District Court for the District of Delaware’s Decision That Eagle Pharmaceuticals, Inc.'s Vasopressin Product Does Not Infringe on Any of the Patents Asserted by Par Pharmaceutical, Inc

Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court

Consensus revenue estimates fall by 21%

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Price target decreased to US$43.00

Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M

Eagle Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Michael Moran Separates as Executive Vice President, Chief Commercial Officer of Eagle Pharmaceuticals, Inc